Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 6, 2001, Pages 519-524

  Bier, Henning ^a   Hoffmann, Thomas ^a   Hauser, Ulrich ^a   Wink, Michael ^b   Öchler, Martin ^b   Kovar, Andreas ^c   Müser, Matthias ^c   Knecht, Reinald ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c MERCK KGAA   (Germany)

Author keywords

EGF receptor; Head and neck cancer; Monoclonal antibody; Phase I study

Indexed keywords

EMD 55 900; EMD 72 000; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LIVER TOXICITY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; HYPOPHARYNX; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; PHARYNGEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0035001584     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000270     Document Type: Article

References (26)

1. 1. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnet K, Falcey J, Anderson V, Waksal H, Mendelsohn J (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904
2. 2. Bier H, Hoffmann T (1996) Epidermal growth factor receptor in head and neck squamous cell carcinomas. In: Werner JA, Lippert BM, Rudert H (eds) Head and neck cancer. Advances in basic research. Excerpta Medica International Congress Series 1114, p 225
3. 3. Bier H, Reiffen KA, Haas I, Stasiecki P (1995) Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol 252:433
4. 4. Bier H, Hoffmann T, Haas I, van Lierop A (1998) Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46:167
5. 5. Christensen ME, Engbaeck F, Therkildsen MH, Bretlau P, Nexo E (1995) A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carcinomas: evaluation, interpretations and limitations. Br J Cancer 72:1487
6. 6. Eisbruch A, Blick M, Lee JS, Sacks PG, Gutterman J (1987) Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumors. Cancer Res 47:3603
7. 7. Faillot T, Magdelenat H, Mady E, Stasiecki P, Fohanno D, Gropp P, Delattre JY (1996) A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 39:478
8. 8. Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579
9. 9. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824
10. 10. Hoffmann T, Hafner D, Balló H, Haas I, Bier H (1997) Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res 17:4419
11. 11. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935
12. 12. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J (1984) Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002
13. 13. Mendelsohn J (1990) The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol 1:339
14. 14. Modjtahedi H, Styles JM, Dean C (1993) The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br J Cancer 67:247
15. 15. Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, Dean C (1994) Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 54:1695
16. 16. Modjtahedi H, Hickisch T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M (1996) Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR 62 in head and neck or lung cancer. Br J Cancer 73:228
17. 17. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M (1987) Binding of antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 225:549
18. 18. Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B (1986) Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 149:9
19. 19. Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H (1987) Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell independent effects. Cancer Res 47:3592
20. 20. Rodeck U, Williams N, Murthy U, Herlyn M (1990) Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha. J Cell Biochem 44:69
21. 21. Salomon DS, Brandt R, Ciardello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183
22. 22. Schmiegel W, Schmielau J, Henne-Bruns D, Juhl H, Roeder C, Buggisch P, Onur A, Kiemer B, Kalthoff H, Jensen EV (1997) Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc Natl Acad Sci USA 94:126
23. 23. Scoog LA, Vokes FE (1994) Chemotherapy, biologics and chemoprevention as systemic therapies for head and neck cancer. Curr Opin Oncol 6:22
24. 24. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY (1996) Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 55 900 in patients with recurrent malignant glioma. Eur J Cancer 32:636
25. 25. Sturgis EM, Sacks PG, Masui H, Mendelsohn J, Schantz SP (1994) Effects of anti-epidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. Otolaryngol Head Neck Surg 111:633
26. 26. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241